Get started
Author

Nicole Stivers

Observed names: N. Stivers, Nicole Chmielewski Stivers, Nicole Chmielewski-Stivers
ORCID: 0000-0001-9635-0256
Observed ORCID: 0000-0001-9635-0256
OpenAlex ID: A5037327861
Sex-Specific Differences in Toxicity Following Systemic Paclitaxel Treatment and Localized Cardiac Radiotherapy
2021 · Nicole Chmielewski Stivers, Benoit Petit, et al. · Cancers · 20
PDF
MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data
2025 · Adam M Brufsky, Kent F Hoskins, et al. · JNCI Cancer Spectrum · 19
PDF
Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline.
2024 · Joyce O'Shaughnessy, Cathy Lynne Graham, et al. · Journal of Clinical Oncology · 11
PDF
Identification of racial disparities across MammaPrint and BluePrint subtypes in HR + HER2- breast cancer
2026 · Sonya Reid, Lindsay Venton, et al. · npj Breast Cancer · 3
PDF
Abstract PS2-07-03: Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2- early-stage breast cancer
2026 · J. O'Shaughnessy, A. Brufsky, et al. · Clinical Cancer Research · 1
Abstract PS4-04: MammaPrint® and BluePrint® predict pathological response to neoadjuvant chemotherapy in patients with HR+HER2- early-stage breast cancer enrolled in FLEX
2025 · Joyce O’Shaughnessy, Priyanka Sharma, et al. · Clinical Cancer Research · 1
Abstract P2-08-12: Prediction of Chemotherapy Benefit by MammaPrint® in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
2025 · Adam Brufsky, Kent Hoskins, et al. · Clinical Cancer Research · 1
Association of MammaPrint and clinical outcomes by race among 5000 individuals with HR+HER2- early stage breast cancer enrolled in FLEX.
2025 · Erin Frances Cobain, Priyanka Sharma, et al. · Journal of Clinical Oncology · 1
Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King
2025 · Rakhshanda Layeequr Rahman, Alfredo Santillan, et al. · International Journal of Molecular Sciences · 1
PDF
Pediatric B-acute lymphoblastic leukemia presenting with a mass: an underrecognized association
2022 · Nicole Stivers, Zeinab Afify · Blood · 1
PDF
Prediction of Anthracycline Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study
2026 · Joyce O'Shaughnessy, Adam M. Brufsky, et al. · JCO Precision Oncology
PDF
Integration of molecular subtyping and immune profiling to predict pathologic complete response in HER2+ breast cancer treated with neoadjuvant dual HER2 therapy.
2026 · David B. Page, Ahmed Elkhanany, et al. · Journal of Clinical Oncology
Association of the 70-gene assay and homologous recombination deficiency in patients with high risk 2 breast cancers.
2026 · Steven J. Isakoff, V.K. Gadi, et al. · Journal of Clinical Oncology
Whole transcriptome analysis reveals MammaPrint and BluePrint-associated gene expression patterns with early lymph node metastasis in early-stage breast cancer
2026 · Faisal Fa’ak, Josien Haan, et al. · Breast Cancer Research and Treatment
PDF
65P Prognostic performance of MammaPrint in patients with small T1a, b, and c node-negative early breast cancer
2026 · E. Shagisultanova, V. Borges, et al. · ESMO Open
Abstract PS5-04-19: 70-gene signature high risk classification provides stronger prognostic value than histologic grade in hr+ her2- early breast cancer
2026 · E. F. Cobain, L. Pusztai, et al. · Clinical Cancer Research
Abstract PS4-09-09: Distinct Immune and Metabolic profiles in Latin American breast cancer patients with obesity enrolled in FLEX
2026 · M. Mazo Canola, A. Santillan, et al. · Clinical Cancer Research
Abstract P2-08-26: FLEX: A Real-World Evidence, Full Transcriptome Study in 30,000 Patients with Early-Stage Breast Cancer
2025 · Robert Maganini, Ellis Levine, et al. · Clinical Cancer Research
Abstract PS2-08: Association of MammaPrint® with gene expression pathways predictive of resistance to cyclin-dependent kinase inhibition
2025 · Adam Brufsky, VK Gadi, et al. · Clinical Cancer Research
Abstract P1-11-24: Neoadjuvant Chemotherapy for T3 tumors in the Era of Precision Medicine - Biology is Still King
2025 · Rakhshanda Rahman, Laura Lee, et al. · Clinical Cancer Research
Association of ImPrintTN signature with survival outcomes by race in basal-type triple negative breast cancer (TNBC): FLEX registry analysis.
2025 · Priyanka Sharma, Shane R. Stecklein, et al. · Journal of Clinical Oncology
70P The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis
2025 · A.M. Brufsky, W. Audeh, et al. · ESMO Open
PDF
310P Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2- breast cancer
2024 · S. Reid, J.G. Whisenant, et al. · Annals of Oncology
PDF
Hemophagocytic lymphohistiocytosis associated with T cell acute lymphoblastic leukemia
2021 · Maria Carter‐Febres, Nicole Stivers, et al. · International Journal of Laboratory Hematology
Works count: 24
Citation count: 59
H-index: 3
I10-index: 3
Year
Topic
Type